New Treatment Methods Launch a Shift in CRC TreatmentMarch 13th 2021
Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.
Nivolumab/Chemo Granted Priority Review for Frontline Metastatic Gastric, GEJ, and Esophageal CancerJanuary 20th 2021
The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) in combination with a fluoropyrimidine- and platinum-containing chemotherapy for use in patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal adenocarcinoma.
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2+ Gastric AdenocarcinomasJanuary 16th 2021
The FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with locally advanced or metastatic HER2-postive gastric or gastroesophageal (GEJ) adenocarcinoma who previously received a trastuzumab-based regimen.
Team Up, Be Aggressive: Improving Outcomes for Metastatic Colon CancerJanuary 14th 2021
The management of patients with colorectal liver metastases is complicated and requires careful assessment from a multidisciplinary tumor board—especially in light of recent advances made with chemotherapy, according to Michael J. Cavnar, MD.
FDA Gives Priority Review to Frontline Pembrolizumab/Chemo for Esophageal/GEJ Cancer SubsetDecember 18th 2020
The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy as a first-line treatment in patients with locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.
Personalized Treatment Is Paramount in Colorectal CancerNovember 17th 2020
Colorectal cancer (CRC) treatment has entered an era that is both exciting and challenging, according to Nilofer S. Azad, MD, who emphasized that as new strategies continue to be explored, treatment decisions should be informed by tumor location, the alterations present, and tolerability.
Priority Review Granted to Trastuzumab Deruxtecan for HER2+ Metastatic Gastric CancerOctober 29th 2020
The FDA has accepted and granted a priority review designation to a supplemental biologics license application for the antibody-drug conjugate (ADC) trastuzumab deruxtecan (Enhertu) for use in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Clinical Trials Will Change the Metastatic Pancreatic Cancer LandscapeOctober 16th 2020
Clinical trials should not be viewed as a last resort for patients with metastatic pancreatic cancer, explained Allyson Ocean, MD, who added that even frontline standards of care should be considered after exhausting all available study options.
Germline Testing for Lynch Syndrome: More Important Than EverOctober 4th 2020
With the emergence of several targeted treatments that have shown efficacy in individuals with germline pathogenic variants, specifically in DNA mismatch repair, the need for germline genetic testing has become even more pronounced.
DKN-01 Gets Fast-Track Status for Gastric and GEJ CancerSeptember 25th 2020
The FDA has granted a fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression, who have progressed on or after a fluoropyrimidine- and platinum-containing chemotherapy, and HER2/neu targeted therapy, if appropriate.
Novel Molecule Enhances Immunotherapy Response in CRC, According to Early DataSeptember 19th 2020
The advent of immunotherapy has revolutionized multiple areas of cancer treatment, said Timothy Cragin Wang, MD, who added that the transformative potential of the modality has been mild at best in the field of colorectal cancer (CRC).
Colorectal Cancer Treatment Continues to Be PersonalizedSeptember 3rd 2020
The management of metastatic colorectal cancer (mCRC) continues to become more personalized, with care decisions being based on factors ranging from the patient’s primary tumor location, to performance status, to the presence of specific mutations, according to Axel Grothey, MD, and novel approaches emerging in later lines are helping to further improve outcomes.
New Advancements Change HCC TreatmentAugust 23rd 2020
Following a period of stagnation, rapid advances have been made in the treatment of patients with hepatocellular carcinoma (HCC), according to Bradley G. Somer, MD, but as more options emerge in all lines of treatment, sequencing approaches will require careful consideration.
Nivolumab Plus Chemotherapy Improves Survival Outcomes in Gastric and Esophageal CancersAugust 13th 2020
Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
Identifying Colorectal Cancer by Blood TestAugust 5th 2020
The novel multimodal FirstSightCRC test has shown promise in identifying colorectal cancer (CRC), as well as precancerous polyps and advanced adenomas, said Shai Friedland, MD, who added that results from the blood-based assay can inform whether a patient should undergo a colonoscopy.
Personalized Treatments in Pancreatic Cancer: The Progress ContinuesAugust 3rd 2020
Although pancreatic cancer has been a historically difficult disease to treat, the emergence of novel combinations have allowed for more patients to receive later lines of therapy, and recent advances have inspired a shift to more personalized treatment approaches to improve outcomes, according to Syma Iqbal, MD.
Surgical Delays May Increase GI Cancer RiskJuly 16th 2020
In light of the COVID-19 pandemic, many elective surgical procedures had been cancelled or rescheduled to maximize hospital capacity and prevent unnecessary exposure for patients, but surgical delays might lead to worse outcomes for certain patients with gastrointestinal cancers.
Drug Duo Is Promising in Older Patients With Advanced HCCJuly 5th 2020
The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) demonstrated comparable clinical activity and safety versus sorafenib (Nexavar) in older and younger patients with previously untreated, unresectable hepatocellular carcinoma (HCC).
FDA Approves Frontline Pembrolizumab for MSI-H/dMMR Metastatic CRCJune 30th 2020
The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer. This marks the first immunotherapy approved for this patient population as a first-line treatment and which is administered to patients without also giving chemotherapy.
Margetuximab Granted Orphan Drug Status for Gastric CancerJune 7th 2020
The FDA has granted margetuximab an Orphan Drug designation for the treatment of patients with gastric and gastroesophageal junction (GEJ) cancer, according to MacroGenics, Inc., the manufacturer of the Fc-engineered monoclonal antibody.